key: cord-0746570-c0payirv authors: Gastine, S.; Pang, J.; Boshier, F. A. T.; Carter, S. J.; Lonsdale, D. O.; Cortina-Borja, M.; Hung, I. F. N.; Breuer, J.; Kloprogge, F.; Standing, J. F. title: Systematic review and patient-level meta-analysis of SARS-CoV-2 viral dynamics to model response to antiviral therapies date: 2020-08-23 journal: nan DOI: 10.1101/2020.08.20.20178699 sha: a6adaa75e9e1bcb3dc63e667d4ba1227c42bcb51 doc_id: 746570 cord_uid: c0payirv Background: SARS-CoV-2 viral loads change rapidly following symptom onset so to assess antivirals it is important to understand the natural history and patient factors influencing this. We undertook an individual patient-level meta-analysis of SARS-CoV-2 viral dynamics in humans to describe viral dynamics and estimate the effects of antivirals used to-date. Methods: This systematic review identified case reports, case series and clinical trial data from publications between 1/1/2020 and 31/5/2020 following PRISMA guidelines. A multivariable Cox proportional hazards regression model (Cox-PH) of time to viral clearance was fitted to respiratory and stool samples. A simplified four parameter nonlinear mixed-effects (NLME) model was fitted to viral load trajectories in all sampling sites and covariate modelling of respiratory viral dynamics was performed to quantify time dependent drug effects. Findings: Patient-level data from 645 individuals (age 1 month-100 years) with 6316 viral loads were extracted. Model-based simulations of viral load trajectories in samples from the upper and lower respiratory tract, stool, blood, urine, ocular secretions and breast milk were generated. Cox-PH modelling showed longer time to viral clearance in older patients, males and those with more severe disease. Remdesivir was associated with faster viral clearance (adjusted hazard ratio (AHR) = 9.19, p<0.001), as well as interferon, particularly when combined with ribavirin (AHR = 2.2, p=0.015; AHR = 6.04, p = 0.006). Interpretation: Combination therapy including interferons should be further investigated. A NLME model for designing and analysing viral pharmacodynamics in trials has been established. This individual patient level meta-analysis provides insight into the natural history of the SARS-CoV-2 viral dynamics 80 through the biggest serial viral load data set available to date. A NLME viral dynamics model was established enabling 81 estimation of the impact of drug effects on viral clearance. The full data set and model code is available to as a tool to design 82 and analyse Phase II antiviral trials. 83 84 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 23, 2020. . https://doi.org/10.1101/2020.08.20.20178699 doi: medRxiv preprint Finding antivirals that target severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) will be crucial in managing 86 the ongoing pandemic. In addition to the development of novel agents, substantial efforts are underway to establish whether 87 currently available agents may be re-purposed 1 . A key biomarker for clinical antiviral activity is viral load in bodily fluids 88 and assessing a drug's or drug combination's ability to reduce viral load is an important first step in identifying therapies that 89 influence clinical outcome. 90 91 To correctly assess antiviral activity, it is first necessary to understand viral load natural history. As a rapidly progressing, 92 primarily respiratory viral infection, SARS-CoV-2 elimination from the body seems to be mainly driven by a combination of 93 innate immune response and exhaustion of target cells available for infection 2 . Observational cohort studies published to date 94 have shown that the rate of viral load decline seems slower in older patients, those with more severe disease and those with 95 comorbidities such as diabetes mellitus and immunosuppression [3] [4] [5] [6] . Interpreting these observational studies requires caution 96 because patients have often received antiviral therapies. Due to the time point of initial infection being unknown, assessing 97 viral load in response to treatment must account for time since symptom onset 7 . 98 99 Since February 2020 case reports and case series of patient-level viral dynamics have been published, some of which report 100 dosing of antiviral drugs 8 . Clinical trials of antivirals and their association with viral load are also beginning to read out 9 . 101 Meanwhile large pragmatic trials of repurposed monotherapy antivirals have yet to find a clearly effective agent 10 . At this 102 crucial juncture, it is vital to develop a pharmacodynamic modelling framework that can be used to describe the natural 103 history of SARS-CoV-2 viral dynamics, make initial estimates on antiviral efficacy of agents used to-date, and to design and 104 evaluate Phase II trials using viral load as a biomarker. 105 106 This systematic review therefore aimed to search for case reports, case series and clinical trials reporting serial individual 107 patient-level SARS-CoV-2 viral load measurements in humans from any sampling site upon which an individual patient-108 level meta-analysis was then performed. A nonlinear mixed effects (NLME) viral dynamic model was fitted to describe the 109 viral trajectories in each sampling site and to give a quantitative measure of viral dynamics. In data of sufficient quality, the 110 8 Data extraction 142 Viral loads were reported as either numerical values in tables, figures, or in viral load versus time plots. Where possible, 143 numerical values were copy-pasted directly into a comma separated value (csv) format from the source, whereas tabulated 144 numerical values contained in pdf images were extracted using https://extracttable.com/. Viral loads reported in plots were 145 extracted using Web Plot Digitizer 12 . 146 147 Each viral load was paired with a time since symptom onset or in asymptomatic subjects, the time since viral monitoring 148 started. Furthermore, sampling site and, if viral load not reported in copies/mL, the PCR assay including the primers used, 149 were extracted along with limit of quantification and limit of detection, if available. In addition, a standardised disease score was constructed for each patient as follows: 158 0 -asymptomatic 159 1 -mild disease (fever, cough or other mild symptoms reported) 160 2 -moderate disease (in addition to mild criterion: need for supplemental oxygen /non-invasive ventilation) 161 3 -severe disease (requirement for mechanical ventilation) 162 All data were stored on a shared github repository, and standardised R-scripts took data from each paper to merge into a 163 single master dataset. A quality control (QC) check on viral load values and all covariates was performed for each paper by 164 an independent reviewer. 165 166 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted August 23, 2020. . Data quality assessment 167 Viral load quality score 168 Two quality assessments were applied to each dataset. Firstly, the quality of viral load reporting was rated on a 1-3 scale. 169 The highest quality 1 was assigned to studies reporting viral load in copies/mL or reporting a calibration curve allowing for 170 direct conversion of Ct values to viral load. Quality 2 was assigned if viral load was reported in PCR Ct and primers used in 171 the assay were reported, but calibration data was missing. In this case a published calibration curve for that primer from 172 another source was used to convert to viral load in copies/mL 13, 14 . Where more than one calibration curve was available for 173 the same primer the mean slope and intercept was used. The lowest (quality score 3) was assigned when viral load was 174 reported in PCR Ct but no further information was available on the PCR assay. In this instance a conversion to copies/mL 175 was made using the mean slope and intercepts from all calibration curves. 176 177 Drug quality score 178 The second quality assessment on a 3-point scale related to reporting of the antiviral drug therapy administered: which drug(s) 179 and upon which days did patients receive the drug(s). The highest quality 1 was assigned when it was reported which days 180 each patient received each drug, or these data were provided by corresponding authors. If it was reported that no antiviral 181 was administered this was also assigned quality 1. Quality 2 was assigned when antiviral drug treatment was reported, but 182 ascertaining which days the patient had received the drugs was not possible. The lowest category, quality 3, was assigned 183 when it was not possible to determine whether or not antivirals had been administered. 184 185 Statistical analysis 186 Primary analysis of time to viral clearance using Cox proportional hazards modelling 187 The primary analysis was conducted on observed time to viral clearance, which was analysed fitting Cox proportional hazards 188 regression models with adjusted hazard ratios estimated for each covariate. We verified the assumptions of proportional 189 hazards using the Therneau-Grambsch test. 15 The data used for this analysis were limited to respiratory and stool sampling 190 sites only, as virus was found to be mostly undetectable at other sites. Furthermore, only data from patients with known 191 antiviral history (drug quality 1 and 2) were used. To assess the possible risk of bias in different drug and viral load qualities, 192 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted August 23, 2020. . https://doi.org/10.1101/2020.08.20.20178699 doi: medRxiv preprint the analysis was repeated on two further subsets: Firstly, with only drug quality 1 and respiratory samples, and secondly on 193 assay quality 1 data only. 194 195 Time to viral load dropping below the limit of detection was modelled with Cox proportional hazards regression in R (version 196 3·6·3) 16 . Where a single patient contributed samples from multiple sampling sites (e.g. upper respiratory and stool), the time 197 to the last site testing negative was used. Multivariable models for covariate effects on time to viral clearance were fitted, 198 with additional interaction terms for drug therapies included, where multiple antiviral agents were given simultaneously. In 199 studies reporting sex as a proportion of males, 10 000 datasets were simulated using the reported fraction of males to randomly 200 assign individuals to being male from the binomial distribution. The Cox proportional hazards regression model was then 201 fitted to each dataset and parameter estimates compared with the model, where individual sex was assigned by rounding the 202 fraction of males. Model parameter estimates were visualised using forest plots. 203 Secondary analysis antiviral pharmacology model 204 The secondary analysis was to use a NLME model to quantify the increase in viral elimination rate with antiviral therapy. 205 This analysis used data only from respiratory samples and rated drug quality 1. 206 Nonlinear mixed-effects (NLME) viral dynamic model 207 Firstly, a descriptive analysis of all data was undertaken. A NLME viral dynamics model was fitted to the individual patient-208 level viral load versus time data. The structural model was based on the general target cell limited model, which has 209 previously been used to describe respiratory viral infections 7, 17 . This model consists of three ordinary differential equations 210 relating to changes in uninfected target cells (T), infected target cells (I) and free virus (V) over time (t), as follows: 211 where β is the rate at which target cells become infected in the presence of virus, δ is the death rate of infected cells, ρ is the 215 rate of viral production from infected cells and c is the rate of clearance of free virus. This model is structurally unidentifiable, 216 as tested through the IdentifiabiltyAnalysis package in Wolfram Mathematica 12·1 (Wolfram Research, Illinois, USA) 18 , 217 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted August 23, 2020. . unless the initial condition for T, β, or ρ are known. Furthermore, the elimination rate of free virus (c) is likely to be much 218 faster than the death rate of infected cells (δ). Hence, by assuming a quasi-steady-state between I and V, and normalising the 219 total cell number by the number of infected cells when observations begin (t = 0), it is then possible to reduce the model to a 220 structurally identifiable, two state ordinary differential equation model relating to the fraction (f) of infected cells with time 221 and infected cells as a proxy for viral load as follows 19 : 222 with γ, a new parameter equal to ρβT0/c and interpreted to be the maximum rate of viral replication. δ can now be interpreted 225 as overall viral elimination rate. This population model was then fitted to viral load data with time using the following form: 226 where yij was the viral load from subject i at time tij, f is the nonlinear model defined above with parameters φi, and εij the 228 residual between the model prediction and the observed data. 229 230 Four parameters were estimated: the initial viral load at symptom onset (V0), β, δ and γ. Interindividual variability was 231 estimated for V0, β and δ with each assumed to follow a log-normal distribution. Viral loads were log transformed and the 232 residual error was assumed to follow a normal distribution. Parameter estimation by maximum likelihood was undertaken 233 using the stochastic approximation expectation maximization (SAEM) in NONMEM version 7·4 20 . Model evaluation was 234 undertaken by analysis of normalised prediction distribution errors (NPDE) and visual predictive checks (VPC) 21 . Viral 235 loads below the limit of detection (LOD) were included by integrating the density function from minus infinity to the limit 236 of detection to yield a probability of the data being below the LOD ("M3 Method") 22 . 237 In some participants, multiple samples were taken at the same time point (either different sampling site or the same sample 238 assayed by more than one method). In this case a common residual error term was used to allow for modelling one-level 239 nested random effects. 240 241 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 23, 2020. . Descriptive analysis of viral shedding by sample site 242 The above model was fitted to data from each sampling site. The resulting parameters were then used to simulate the overall 243 population viral load trajectories. For the respiratory sample sites viral area under the curve (AUC), peak viral load and half-244 life were derived from the model and plotted versus patient covariates. 245 Covariate analysis and antiviral drug effects modelling 246 The initial model used only data obtained in untreated patients. A covariate analysis was undertaken testing the influence of 247 sampling site (nasal versus oral versus lower respiratory tract), sex, age and disease status on either V0, β or δ. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 23, 2020. . https://doi.org/10.1101/2020.08.20.20178699 doi: medRxiv preprint 13 Results of the systematic search are given in Figure 1 , and details of included papers in Table 1 Metrics of the full data set are given in Supplementary Table S1 . 277 278 Full details of the extracted patient-level covariates are given in Table 2 . Recording of fever, days on ICU and days ventilated 279 was largely unavailable. Therefore, no further analysis was performed on these variables. However, it was possible to 280 categorise disease status in all drug quality 1 and 2 papers, either through reports in the manuscript or by contacting 281 corresponding authors. Overall, most patients had mild disease (376, 66·8%), whereas 79 (14·0%) patients had moderate and 282 84 (14·9%) severe disease. In total 24 (4·3%) asymptomatic patients were reported. 283 The distribution of recorded drug therapies, available for drug quality 1 data and respiratory site samples, is summarised in 284 Supplementary The NLME model fits to the overall data, stratified by sampling site, are provided in Supplementary Table S3 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 23, 2020. . https://doi.org/10.1101/2020.08.20.20178699 doi: medRxiv preprint were associated with longer time to viral clearance and viral clearance was faster in females, younger patients and those who 295 were asymptomatic. 296 297 Regarding antiviral therapies, only remdesivir (adjusted hazard ratio (AHR) = 9·19, p<0·001) and interferons (AHR = 2·20, 298 p =0·015) were independently associated with faster viral clearance. The effect of interferon alpha and beta (Supplementary 299 Figure S3 ) was similar and hence these were combined. Lopinavir/ritonavir, ribavirin and interferons were most used and 300 also most used in combination. Adding interaction terms for interferon plus lopinavir/ritonavir, interferon plus ribavirin and 301 lopinavir/ritonavir plus ribavirin showed a trend towards synergy between interferons and ribavirin in the full dataset (AHR 302 = 6·04, p=0·006 Figure 3 ), as well as in the additional analysis taking in quality assessments to account for potential bias: 303 respiratory data limited to drug quality 1 ( Figure 4) from the first month of life to 100 years. Data from all major sampling sites showed, that: following symptom onset in most 320 patients, upper respiratory tract viral load has peaked and is declining, whereas in the lower respiratory tract viral load peaks 321 2-3 days after symptom onset; virus is detectable in stool for at least 2 weeks in 75% of individuals, and virus is detected in 322 low levels in blood, urine, ocular secretions and breast milk (Figure 2 ). In addition to simulating the expected trajectory of 323 viral load at each site, we were able to simulate the percentage of samples expected to be below a typical detection limit of 324 10 copies/mL (Figure 2 ). From this it can be seen, that from day 10 post symptom onset over a quarter of upper respiratory 325 samples have undetectable viral load. This emphasises the importance of early antiviral therapy, and for Phase II trials using 326 viral load as an endpoint to commence therapy in the first few days of symptom onset in order to reliably differentiate antiviral 327 effects from natural viral decline ( Figure 5 , Supplementary Table S5) . 328 329 A heterogeneous range of antivirals, administered in different combinations, was observed in our data (Supplementary Table 330 S2) meaning multivariable modelling of time to viral clearance was used to tease out individual drug effects. No antiviral 331 activity was seen for chloroquine/hydroxychloroquine, azithromycin, lopinavir/ritonavir, umifenovir and thymalfasin. 332 However, remdesivir and interferons were both independently associated with shorter time to viral clearance and combination 333 of interferons with ribavirin also appeared to reduce viral load compared with untreated patients (Figures 3, 4 and S4) . 334 Remdesivir did not however significantly decrease δ in the NLME model, but this is likely due to the low number of included 335 patients. 336 Our most interesting finding is the promising antiviral activity of interferons, possibly due to low endogenous interferon 338 levels induced by SARS-CoV-2 27,28 . Interferons (alpha and beta) have shown extensive in vitro activity against Severe acute 339 respiratory syndrome-1 (SARS-CoV-1) and Middle East respiratory syndrome coronavirus (MERS-CoV) 23, 24 .However, this 340 has not translated into clinical effectiveness in MERS-CoV 23 , although results from one trial are still pending 25 . Although 341 recent data suggests interferon beta may be more potent than alpha against SARS-CoV-2 in vitro 26 , possibly due to higher 342 selective indices for interferon-beta 1b, upon finding similar effects of interferon alpha and beta in our primary analysis 343 ( Figure S3 ), we decided to combine the interferon effect to better explore drug combinations. Consistent across data qualities 344 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 23, 2020. . https://doi.org/10.1101/2020.08.20.20178699 doi: medRxiv preprint and sampling site combinations, we found either a significant or trend towards significant synergistic activity of interferon 345 plus ribavirin (Figures 3, 4, S4) . Table S5 ). In SARS-CoV-1 however, lopinavir/ritonavir 362 plus ribavirin was found to be synergistic in vitro and when initiated immediately upon diagnosis led to a significant decrease 363 in mortality compared to historical controls 30, 31 . Early post-exposure prophylaxis against Middle East Respiratory Syndrome 364 (MERS-CoV) in healthcare workers showed that lopinavir/ritonavir plus ribavirin reduced the incidence of infection from 365 28% to 0% 32 . The lopinavir/ritonavir plus ribavirin combination has therefore been the basis for many clinical trials and 366 treatment protocols, but our findings suggest that it may not be as useful in SARS-CoV-2 ( Figure 3) . showing promising in vitro activity, we did not find significant antiviral effects of azithromycin, 371 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 23, 2020. . https://doi.org/10.1101/2020.08.20.20178699 doi: medRxiv preprint chloroquine/hydroxychloroquine, thymalfasin or umifenovir. In the case of hydroxychloroquine and azithromycin the raw 372 viral load data from the heavily criticised study by Gautret et al 33 was included, but contrary to the original analysis we found 373 no clinical antiviral activity of either drug and, in the case of hydroxychloroquine, a trend towards slower viral clearance. 374 The reason for this difference in interpretation appears to stem from using time since symptom onset as opposed to time since 375 starting drug and with untreated patients being monitored from an earlier day-post symptom onset. This example highlights 376 the necessity of accounting for the time course of the infection when analysing viral loads. 377 378 In our secondary NLME analysis the simplified target cell limited model provided a good fit to data from each sampling site. 379 In many cases this approximated a mono-exponential decay, but in others, particularly in lower respiratory tract, there was a 380 pronounced peak in the first days following symptom onset. The model was stable with high inter-individual variability on 381 V0 and β, reflecting the fact that relative changes in these parameters lead to the initial part of the curve either rising then 382 falling (in situations when V0 ≈ -β) or approximately monoexponentially declining (when V(0) >> -β). In addition, we found 383 the model to be less sensitive to changes in γ, meaning it can take a wide range of values with little influence on model fit, 384 hence we did not estimate an inter-individual variability term on it. 385 386 In contrast to authors who have estimated parameters for more mechanistic models 34 , we estimated all drug effects to increase 387 δ, which implies a mode of action relating to inhibition of viral replication or stimulation of viral clearance mechanisms. 388 Whilst for most of the drugs studied this may be reasonable, entry inhibitors may be more appropriately described by 389 inhibition of γ, which may not be statistically identifiable with the data possible to collect in the clinical setting. Despite this 390 potential limitation, we found similar agents (combinations including interferons, ribavirin and lopinavir/ritonavir) to those 391 identified in the primary analysis of time-to viral clearance. 392 The major limitation of our work is the lack of clinical trial data and lack of data on potentially important re-purposing agents 394 such as favipiravir and nitazoxanide and that only one of the authors of a major clinical trial agreed to share their data 9 . 395 Through applying quality assessment criteria on drug history and assay reporting, before undertaking Cox proportional 396 hazards and NLME modelling we aimed to reduce possible bias in the heterogenous data available. 397 398 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 23, 2020. . https://doi.org/10.1101/2020.08. 20.20178699 doi: medRxiv preprint In conclusion, this individual patient level meta-analysis has yielded useful insights into SARS-CoV2 viral dynamics. A 399 model-based description of viral trajectories in different sampling sites has been elucidated, and we have found covariates 400 such as increasing age, disease severity and male sex to be associated with slower viral clearance. Our review firmly 401 establishes a role for early viral suppression in the management of SARS-CoV-2 and an important signal as to the possible 402 benefits of interferons as a component of antiviral therapy has been found. It has been shown that viral dynamic models such 403 as ours can increase the power to detect drug effects due to their utilisation of serial measures 35 and our model should be 404 useful to others in both the design and analysis of future Phase II trials, hence the model code and raw data from this analysis 405 is made available. 406 407 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 23, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 23, 2020. . https://doi.org/10.1101/2020.08.20.20178699 doi: medRxiv preprint *There is discord between the reported ICU and mechanical ventilation and disease severity score due to incomplete reporting in some papers. Disease severity was taken from individual reports of disease status in cases where ICU admission and invasive ventilation were not specifically mentioned, and only Disease severity was used in the analyses. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 23, 2020. . Phan LT, Nguyen TV, Huynh LKT, et al. Clinical features, isolation, and complete genome sequence of severe acute respiratory syndrome coronavirus 2 from the first two patients in Vietnam. J Med Virol 2020. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 23, 2020. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 23, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 23, 2020. Black lines are the median predictions, with shaded areas representing the 95% prediction interval. The percentage of samples that are predicted to be below a typical limit of detection (10 copies/mL) are given in 2-daily time bins on each plot . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 23, 2020. 80+ female male asymptomatic mild moderate severe no yes no yes no yes no yes no yes no yes no yes no yes no yes no yes 297 20 317 125 121 58 13 135 182 16 239 44 18 299 18 294 23 311 6 297 20 234 83 132 185 219 98 258 59 259 58 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted August 23, 2020. . https://doi.org/10.1101/2020.08.20.20178699 doi: medRxiv preprint ifn + lpvr/r + riba, day 1 ifn + lpvr/r + riba, day 3 ifn + lpvr/r + riba, day 7 ifn + lpvr/r + riba, day 10 lpvr/r + ribavirin, day 1 lpvr/r + ribavirin, day 3 lpvr/r + ribavirin, day 7 lpvr/r + ribavirin, day 10 interferon + ribavirin, day 1 interferon + ribavirin, day 3 interferon + ribavirin, day 7 interferon + ribavirin, day 10 ribavirin, day 1 ribavirin, day 3 ribavirin, day 7 ribavirin, day 10 lopinavir/ritonavir, day 1 lopinavir/ritonavir, day 3 lopinavir/ritonavir, day 7 lopinavir/ritonavir, day 10 interferon, day 1 interferon, day 3 interferon, day 7 interferon, day 10 Simulations with a dummy population equally distributed between 50 and 100 years, and equal male/female ratio were performed for each scenario. Drugs were started at day 1 (blue), day 3 (orange), day 7 (green) or day 10 (red) post symptom onset. Mean black line and error bars represent simulations of the dummy population without drug treatment. Coloured mean lines and error bars represent the respective drug regimen. Percentage values represent expected proportion of samples below the limit of detection for no drug (black) versus drug therapy (coloured) at each time point. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted August 23, 2020. . https://doi.org/10.1101/2020.08.20.20178699 doi: medRxiv preprint Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study Temporal dynamics in viral shedding and transmissibility of COVID-19 Factors Leading to High Morbidity and Mortality of COVID-19 in Patients with Type 2 Diabetes Novel Coronavirus-19 (COVID-19) in the immunocompromised transplant recipient: #Flatteningthecurve Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China A drug-disease model describing the effect of oseltamivir neuraminidase inhibition on influenza virus progression Viral Load Kinetics of SARS-CoV-2 Infection in First Two Patients in Korea Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement Analytical sensitivity and efficiency comparisons of SARS-COV-2 qRT-PCR primer-probe sets Molecular Diagnosis of a Novel Coronavirus (2019-nCoV) Causing an Outbreak of Pneumonia Proportional hazards tests and diagnostics based on weighted residuals A language and environment for statistical computing (version 3.6.3). R Foundation for Statistical Computing Kinetics of influenza A virus infection in humans Minimal output sets for identifiability Modelling SARS-CoV-2 Dynamics: Implications for Therapy NONMEM 7.4 users guides Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics Ways to Fit a PK Model with Some Data Below the Quantification Limit Pharmacokinetics/Pharmacodynamics of Antiviral Agents Used to Treat SARS-CoV-2 and Their Potential Interaction with Drugs and Other Supportive Measures: A Comprehensive Review by the PK/PD of Anti-Infectives Study Group of the European Society of Antimicrobial Agents Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-beta1b (MIRACLE trial): study protocol for a randomized controlled trial Broad-Spectrum Host-Based Antivirals Targeting the Interferon and Lipogenesis Pathways as Potential Treatment Options for the Pandemic Coronavirus Disease 2019 (COVID-19) Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19 Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19 A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19 Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study Post-exposure prophylaxis for Middle East respiratory syndrome in healthcare workers Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Clinical trial simulation to evaluate power to compare the antiviral effectiveness of two hepatitis C protease inhibitors using nonlinear mixed effect models: a viral kinetic approach A Well Infant With Coronavirus Disease 2019 With High Viral Load Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury Case of the Index Patient Who Caused Tertiary Transmission Infection in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Infected Pneumonia Monitored by Quantitative RT-PCR Viral load of SARS-CoV-2 in clinical samples Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes Clinical features and dynamics of viral load in imported and non-imported patients with COVID-19 Detectable 2019-nCoV viral RNA in blood is a strong indicator for the further clinical severity Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma Evidence from two cases of asymptomatic infection with SARS-CoV-2: Are 14 days of isolation sufficient? Clinical and virological data of the first cases of COVID-19 in Europe: a case series Virological assessment of hospitalized patients with COVID-2019 Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding Sequential analysis of viral load in a neonate and her mother infected with SARS-CoV-2 Saliva is more sensitive for SARS-CoV-2 detection in COVID-19 patients than nasopharyngeal swabs Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan Evaluating the accuracy of different respiratory specimens in the laboratory diagnosis and monitoring the viral shedding of 2019-nCoV infections Persistent viral RNA positivity during the recovery period of a patient with SARS-CoV-2 infection Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States Viral dynamics of SARS-CoV-2 across a spectrum of disease severity in COVID A report of three COVID-19 cases with prolonged viral RNA detection in anal swabs Assessing Viral Shedding and Infectivity of Tears in Coronavirus Disease 2019 (COVID-19) Patients Prolonged virus shedding even after seroconversion in a patient with COVID-19 Prolonged viral shedding in feces of pediatric patients with coronavirus disease 2019 Duration of SARS-CoV-2 viral shedding during COVID-19 infection Clinical Course and Outcomes of Patients with Severe Acute Respiratory Syndrome Coronavirus 2 Infection: a Preliminary Report of the First 28 Patients from the Korean Cohort Study on COVID-19 SARS-CoV-2 Isolation From Ocular Secretions of a Patient With COVID-19 in Italy With Prolonged Viral RNA Detection The index case of SARS-CoV-2 in Scotland SARS-CoV-2 Viral Load in Clinical Samples from Critically Ill Patients Viral dynamics in asymptomatic patients with COVID-19 Factors associated with the duration of viral shedding in adults with COVID-19 outside of Wuhan, China: a retrospective cohort study Viral loads in throat and anal swabs in children infected with SARS-CoV-2 Chronological Changes of Viral Shedding in Adult Inpatients with COVID-19 in Wuhan, China Successful treatment of a centenarian with coronavirus disease 2019 (COVID-19) using convalescent plasma Detectable severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in human breast milk of a mildly symptomatic patient with coronavirus disease 2019 (COVID-19) Clinical Significance of a High SARS-CoV-2 Viral Load in the Saliva 315 23 16 197 157 354 138 131 72 13 139 215 19 258 52 25 335 19 331 23 348 6 333 21 343 11 249 105 147 207 236 118 288 66 287 67 245 109